New study shows that raising levels of fatty aci
Author: Michael
On a mission to promote healthier eating habits,
Transferring regeneration-associated genes from
Company announces PIPE financing of up to $122 m
Part of $27 million fund to foster collaboration
New Alzheimer’s drug data highlights increased
Study identifies the nuclear protein Pin1 as piv
Seed round led by SV Health and Two Bear Capital
Study shows Shingrix vaccine may delay dementia
Cognition Therapeutics reports once-daily drug’s potential to slow Alzheimer’s progression, showing promise with favorable safety profile. Cognition Therapeutics, Inc. recently disclosed findings from their Phase 2 SHINE trial, investigating the efficacy of CT1812, an experimental oral treatment for Alzheimer’s disease. The study, which involved 153 adults with mild-to-moderate Alzheimer’s, assessed the cognitive and functional impacts of daily CT1812 doses over six months, and has reported approximately 40% less cognitive decline in patients administered CT1812 compared with those on a placebo. The SHINE trial, a double-blind, placebo-controlled study, explored two dosages of CT1812 (100mg and 300mg), with the primary objective being…